Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
John C
JC
Reneau
Department of Health Sciences Research, Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Dennis
D
Asante
Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota.|OptumLabs, Cambridge, Massachusetts.
Holly
H
van Houten
Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota.
Lindsey R
LR
Sangaralingham
Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Francis K
FK
Buadi
Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Amir
A
Lerman
Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
Joerg
J
Herrmann
D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000069286:Bortezomib / Q000009:adverse effects* / Q000627:therapeutic use; D066126:Cardiotoxicity; D006331:Heart Diseases / Q000453:epidemiology* / Q000209:etiology* / Q000401:mortality; D006801:Humans; D053208:Kaplan-Meier Estimate; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy / Q000401:mortality; D057216:Propensity Score; D016016:Proportional Hazards Models; D012306:Risk; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide